Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 15.73
(-0.25%)
CNY 15.73
(-0.25%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 652.91 Million CNY | 47.9% |
| 2022 | 441.45 Million CNY | 6523.21% |
| 2021 | 6.66 Million CNY | 408.14% |
| 2020 | 1.31 Million CNY | -95.84% |
| 2019 | 31.51 Million CNY | 291.75% |
| 2018 | 8.04 Million CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 817.21 Million CNY | 27.09% |
| 2024 Q3 | 742.4 Million CNY | -9.15% |
| 2024 Q1 | 643.46 Million CNY | -1.43% |
| 2023 Q3 | 611.7 Million CNY | 7.46% |
| 2023 FY | 652.91 Million CNY | 47.9% |
| 2023 Q4 | 652.91 Million CNY | 6.74% |
| 2023 Q2 | 569.22 Million CNY | -1.48% |
| 2023 Q1 | 577.76 Million CNY | 30.88% |
| 2022 Q3 | 239 Million CNY | 0.18% |
| 2022 Q2 | 238.58 Million CNY | 832.25% |
| 2022 Q1 | 25.59 Million CNY | 283.97% |
| 2022 FY | 441.45 Million CNY | 6523.21% |
| 2022 Q4 | 441.45 Million CNY | 84.7% |
| 2021 Q4 | 6.66 Million CNY | -1.81% |
| 2021 Q1 | 1.26 Million CNY | -3.57% |
| 2021 FY | 6.66 Million CNY | 408.14% |
| 2021 Q3 | 6.78 Million CNY | 516.84% |
| 2021 Q2 | 1.1 Million CNY | -13.01% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 FY | 1.31 Million CNY | -95.84% |
| 2020 Q4 | 1.31 Million CNY | 0.0% |
| 2020 Q3 | - CNY | -100.0% |
| 2020 Q2 | 17.7 Million CNY | 0.0% |
| 2019 FY | 31.51 Million CNY | 291.75% |
| 2019 Q4 | - CNY | 0.0% |
| 2018 FY | 8.04 Million CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |